Insomnia News and Research

Latest Insomnia News and Research

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

FDA approved drug to treat Ph- acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults.

10 Aug 2012

Scientists develop new way to study role of GABA-A receptors in various disorders

A new way to study the role of a critical neurotransmitter in disorders such as epilepsy, anxiety, insomnia, depression, schizophrenia, and alcohol addiction has been developed by a group of scientists led by Gong Chen, an associate professor of biology at Penn State University.

9 Aug 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012.

7 Aug 2012

Researchers develop improved expert system for diagnosis of thyroid disease

Researchers in India have developed an improved expert system for the diagnosis of thyroid disease.

3 Aug 2012

Study: 150 million adults suffer from sleep-related problems across developing world

Levels of sleep problems in the developing world are approaching those seen in developed nations, linked to an increase in problems like depression and anxiety.

1 Aug 2012

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed, Inc. today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.

31 Jul 2012

Sleep related diabetes risk needs attention

Strategies aimed at improving sleep quality among individuals without Type 2 diabetes may act as an additional tool in diabetes prevention, report researchers.

30 Jul 2012

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A. Inc. today announced the filing of a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for a new indication for AMITIZA (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.

26 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

Additional research required to assess effectiveness of herbal remedies for insomnia

Approximately 1 in 3 Americans suffers from chronic sleep deprivation and another 10-15% of the population has chronic insomnia. Sleep disorders can profoundly affect a person's whole life and have been linked to a range of diseases, including obesity, depression, anxiety, and inflammatory disorders.

19 Jul 2012

Vivus receives FDA approval for Qsymia to manage chronic weight

The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

18 Jul 2012

Stress management treatment reduces formation of new brain lesions in people with MS

Research conducted by Jesus Lovera, MD, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has shown that stress management treatment significantly reduced the formation of new brain lesions in people with multiple sclerosis (MS) over the course of treatment.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Psychotic depression now fulfills the criteria for a valid psychiatric syndrome

The number of studies reporting significant and clinically relevant differences between psychotic depression (PD) and non-PD has increased considerably over the past decades. This summary of the current evidence suggests that PD now fulfils the criteria for a valid psychiatric syndrome.

14 Jul 2012

Insomnia News and Research

Latest Insomnia News and Research

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

FDA approved drug to treat Ph- acute lymphoblastic leukemia

Scientists develop new way to study role of GABA-A receptors in various disorders

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Researchers develop improved expert system for diagnosis of thyroid disease

Study: 150 million adults suffer from sleep-related problems across developing world

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Sleep related diabetes risk needs attention

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Insomnia: an interview with Dr Darryle Schoepp

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Additional research required to assess effectiveness of herbal remedies for insomnia

Vivus receives FDA approval for Qsymia to manage chronic weight

Stress management treatment reduces formation of new brain lesions in people with MS

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

UCB’s Neupro now available in U.S. pharmacies

Psychotic depression now fulfills the criteria for a valid psychiatric syndrome

Call for more restricted opioid use

Treatment-resistant insomnia exacerbates major depression

Opioids for chronic noncancer pain discouraged

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Insomnia News and Research

Latest Insomnia News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in